As Marengo Therapeutics Inc. gears up to start human trials with its lead compound, the company nailed down a deal with Ipsen SA worth $45 million up front and as much as $1.59 billion-plus in milestone rewards to advance a pair of candidates from the Selective T Cell Activation Repertoire (STAR) platform into the clinic. Read More
After spending a lot of money and putting in seven years of hard work, Astrazeneca plc is discontinuing its phase III Interlink-1 study of monalizumab. Results from an interim futility analysis and an independent data monitoring committee’s recommendation convinced the company to bring it to a halt. Read More
Apollo Therapeutics Group Ltd. has bought worldwide rights to Avalo Therapeutics Inc.’s anti-IL-18 antibody, camoteskimab, in a deal worth up $89 million, taking on development of the early stage drug for arthritis and potentially other diseases. Read More
During a presentation at the Alzheimer's Association International Conference 2022, researchers from the Genetic Frontotemporal Dementia (FTD) Initiative consortium presented data from a study following nearly 1,300 patients with FTD caused by a genetic mutation, their presymptomatic family members who have the inherited mutation and unaffected family members to serve as controls. Researchers have used data from the study, which has been enrolling patients for over 10 years, to develop biomarkers that can be used to assess progression of FTD in interventional clinical trials. Read More
Inventisbio Co. Ltd. has raised ¥2.084 billion (US$296 million) in an IPO on Shanghai’s STAR Market priced at ¥18.12 per share, though its stock saw a disappointing debut, opening at ¥14 per share on the first trading day July 25 and closing at $15.29, for a drop of 15.6%. The stock closed Aug. 1 at ¥14.42. Read More
As Democrats in the U.S. Senate rush to pass prescription drug pricing reforms through the reconciliation process this week, the nonpartisan Information Technology & Innovation Foundation (ITIF) is offering Japan’s experience with government price controls as a cautionary tale. “Stringent drug price controls have significantly hampered the competitive and innovative capacity of Japan’s biopharmaceutical industry in recent decades, serving as a warning for U.S. policymakers considering introducing Medicare Part D drug price controls in 2022,” according to the ITIF. Read More
The volume of clinical data in 2022 is down by 16.9% from last year. Pandemic efforts are still decreasing while three therapeutic areas dominate the news. Through the last week of July, there have been a total of 1,997 clinical entries, compared with 2,402 by this point in 2021. Read More
A lot of what goes on during aging remains too poorly understood for straightforward translation. There are hallmarks of aging, and researchers are getting a handle on its biological mechanisms. But in a basic sense, “we still don’t have much of an idea what causes aging,” said Björn van Eyss of the Leibniz Institute for Aging Research. Part six of BioWorld’s multipart series on extending the human lifespan explores the moonshot attracting the most attention: in vivo partial reprogramming. Read More
In Extending the human lifespan, a BioWorld special report, the team examined the latest science, the key biological drivers that can be targeted pharmacologically and the companies developing potential “Fountain of Youth” candidate drugs. In this episode of the BioWorld Insider Podcast, the team discussed the report’s highlights and key takeaways.
Please take a few minutes to fill out this short survey to help us provide you with the best possible source of news. Customer feedback is critical so that we can make BioWorld a valuable component of your daily workflow. We want to continue to evolve to serve you. The survey should take just 5 minutes. You can click through to the questions here. Read More
Biopharmas raising money in public or private financings, including: Differentiated, Fennec, Glubio, Nuvectis, Obseva, Oricell, Revelation, Structure, Synthetic and Trevena. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: ACM, Adamis, BMS, Enanta, Gilead, Lynk, Novo, Ovoca, Viiv. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 7 Hills, Akari, Apexigen, Arecor, Bioxcel, Brookline, Cortexyme, Merck, Nuvation, Quince. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Immunitybio, Omeros, Shine. Read More
